Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(14%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
2
29%
Ph phase_1
2
29%
Ph phase_3
2
29%

Phase Distribution

2

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
2(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(5)
Other(1)

Detailed Status

Completed5
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (33.3%)
Phase 32 (33.3%)
Phase 42 (33.3%)

Trials by Status

completed571%
recruiting114%
unknown114%

Recent Activity

1 active trials
Showing 5 of 7
completed

Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants

NCT04477837
recruitingphase_4

Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation

NCT06187311
completedphase_1

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

NCT03083704
completedphase_3

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority

NCT02832544
unknownphase_4

AntiCoagulants and COGnition

NCT04073316
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04477837

Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants

Completed
NCT06187311Phase 4

Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation

Recruiting
NCT03083704Phase 1

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

Completed
NCT02832544Phase 3

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority

Completed
NCT04073316Phase 4

AntiCoagulants and COGnition

Unknown
NCT03926780Phase 3

Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi

Completed
NCT03282643Phase 1

Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7